Full Text View
Tabular View
No Study Results Posted
Related Studies
Thalidomide in Pediatric Inflammatory Bowel Diseases. (TALIBDP)
This study has been completed.
Study NCT00720538   Information provided by IRCCS Burlo Garofolo

First Received on July 18, 2008.   Last Updated on October 25, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Inflammatory Bowel Diseases
Crohn's Disease
Ulcerative Colitis
Additional conditions recognized in this trial
Colitis
Colitis, Ulcerative
Crohn Disease
Intestinal Diseases
Ulcer
More general conditions related to this trial
Colonic Diseases
Digestive System Diseases
Gastroenteritis
Gastrointestinal Diseases
Pathologic Processes
Interventions listed in this trial
Thalidomide
placebo
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
IRCCS Burlo Garofolo
Ospedale Meyer
Pediatric Gastroenterology Unit, IRCCS Gaslini, Genoa.
Vittore Buzzi Children's Hospital
University of Pisa
Pediatric Gastroenterology Unit, University of Messina.
Brescia University
University of Trieste


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services